Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia

Table 2

Initial and current laboratory parameters for weight change among HIV/AIDS patients on ART who enrolled in the ART clinic at Hawassa University Comprehensive Specialized Hospital in March 2021.

Variables	Category	Weight change				Total
		<5		≥5
		TLD	TLE	TLD	TLE
WHO stage	I	22	23	30	22	97
		42.3%	51.1%	57.7%	48.9%	100.0%
	II	21	25	51	21	118
		29.2%	54.3%	70.8%	45.7%	100.0%
	III	24	55	47	51	177
		33.8%	51.9%	66.2%	48.1%	100.0%
	IV	7	8	9	6	30
		43.8%	57.1%	56.3%	42.9%	100.0%
	Total	74	111	137	100	422
		35.1%	52.6%	64.9%	47.4%	100.0%
Initial CD4 count	CD4 <500	40	74	81	64	145
		33.1%	53.6%	66.9%	46.4%	56.0%
	CD4 ≥500	34	37	56	36	92
		37.8%	50.7%	62.2%	49.3%	56.4%
	Total	74	111	137	100	237
		35.1%	52.6%	64.9%	47.4%	56.2%
Current CD4	CD4 <500	34	96	60	57	213
		56.7%	62.7%	100.0%	37.3%	100.0%
	CD4 ≥500	40	15	151	43	209
		26.5%	25.9%	100.0%	74.1%	100.0%
	Total	74	111	211	100	422
		35.1%	52.6%	100.0%	47.4%	100.0%
Viral load after 1 year	Viral load ≥1000	18	35	12	14	79
		60.0%	71.4%	40.0%	28.6%	100.0%
	Viral load <1000	56	76	125	86	343
		30.9%	46.9%	69.1%	53.1%	100.0%
	Total	74	111	137	100	422
		35.1%	52.6%	64.9%	47.4%